nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,source_class,delayed_posting,expanded_access_nctid,expanded_access_status_for_nctid,fdaaa801_violation,pmid_x,number_of_nsae_subjects,minimum_age_num,maximum_age_num,recruitment_details,ci_percent,p_value,description_x,description_y,pmid_y,citation,ae_count,sae_count,mortality_count,num_aes_described
NCT04150250,,2019-10-31,2021-03-01,,2021-03-01,2019-10-31,2019-11-04,Actual,2021-03-01,2021-03-25,Actual,,,,2021-03-01,2021-03-25,Actual,"November 4, 2019",Actual,2019-11-04,February 2021,2021-02-28,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,,Interventional,CAST,All enrolled participants,Cholera Anti-Secretory Treatment Trial,"A Phase 2a Randomized, Single-Center, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Preliminary Efficacy of Oral iOWH032 Against Cholera Diarrhea in a Controlled Human Infection Model",Completed,,Phase 2,47,Actual,PATH,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2022-06-27 19:16:42,2022-06-27 19:16:42,OTHER,,,,,34793441.0,145,18,44,A total of 47 healthy adults were enrolled at one clinical research site in the United States. Participants were confined in an inpatient isolation research ward for a duration of approximately 11 days until discharge criteria were met.,95.0,0.2254,"On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.",Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.,34793441,"Erdem R, Ambler G, Al-Ibrahim M, Fraczek K, Dong SD, Gast C, Mercer LD, Raine M, Tennant SM, Chen WH, de Hostos EL, Choy RKM. A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model. PLoS Negl Trop Dis. 2021 Nov 18;15(11):e0009969. doi: 10.1371/journal.pntd.0009969. eCollection 2021 Nov.",39,1,0,48
NCT01895855,,2013-07-05,2018-07-05,,2021-03-05,2013-07-10,2013-07-11,Estimate,2021-03-05,2021-04-01,Actual,,,,2021-03-05,2021-04-01,Actual,September 2013,,2013-09-30,March 2021,2021-03-31,November 2014,Actual,2014-11-30,November 2014,Actual,2014-11-30,,Interventional,,,"Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination",Completed,,Phase 3,197,Actual,Emergent BioSolutions,,2.0,,,False,,,,True,,,,,,,,,,,No,,2022-06-27 3:55:35,2022-06-27 3:55:35,INDUSTRY,,,,,31743334.0,56,18,45,,95.1,,Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU,Single dose; liquid suspension after reconstitution with buffer; 5x10^8,27001804,"Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21.",34,2,0,36
